Yeji
NDA/BLA filedconf 0.85

taletrectinib — NDA/BLA filed

$NUVB · Nuvation Bio Inc. · advanced ROS1-positive non-small cell lung cancer (NSCLC)
Event date
Date TBD
Sponsor runway
cash-flow +
$533.7M liquid

Evidence

“U.S. Food and Drug Administration\'s acceptance and priority review of the Company\'s New Drug Application for taletrectinib for the treatment of advanced ROS1-positive NSCLC”
Source: 8-K filed 2025-02-12View on EDGAR ↗0001193125-25-025099

Comparable historical nda/bla fileds· last 5 years · same event type

TickerDrugDateOutcome
$AXSM—2025-12-31unknown
$RCKTkresladi2025-10-14unknown
$ALDXreproxalap2025-07-17unknown
$ETONet-6002025-07-08unknown
$BCRXorladeyo (berotralstat)2025-05-14unknown
$CORTrelacorilant2025-03-03unknown
$ALDXreproxalap2024-11-01unknown
$AXSMaxs-072024-09-04unknown
$RCKTkresladi2023-10-02unknown
$GERNimetelstat2023-08-21unknown

Recent insider activity· ±90 days

No insider Form 4 activity reported on $NUVB in the 90 days around this event.
← All catalysts for $NUVB